D. E. Shaw & Co., Inc. Uni Qure N.V. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Uni Qure N.V. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 16,700 shares of QURE stock, worth $252,337. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,700
Previous 299,771
94.43%
Holding current value
$252,337
Previous $5.29 Million
96.66%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding QURE
# of Institutions
173Shares Held
50.8MCall Options Held
2.13MPut Options Held
480K-
Vestal Point Capital, LP New York, NY4.79MShares$72.4 Million3.63% of portfolio
-
Rtw Investments, LP New York, NY4.27MShares$64.5 Million0.74% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.99MShares$60.3 Million3.32% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.76MShares$41.6 Million1.32% of portfolio
-
Abrdn PLC2.75MShares$41.6 Million0.07% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $706M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...